Bibliography
- Merikangas KR, Jin R, He JP, Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011;68:241-51
- World Health Organization. The World health report 2002: reducing risks, promoting healthy life. World Health Organization; Geneva, Switzerland: 2002
- Rouillon F, Gasquet I, Garay RP, Screening for bipolar disorder in patients consulting general practitioners in France. J Affect Disord 2010; [Epub ahead of print]
- Smith DJ, Griffiths E, Kelly M, Unrecognised bipolar disorder in primary care patients with depression. Br J Psychiatry 2011; [Epub ahead of print]
- Hantouche EG, Akiskal HS, Azorin JM, Clinical and psychometric characterization of depression in mixed mania: a report from the French National Cohort of 1090 manic patients. J Affect Disord 2006;96:225-32
- Goodwin FK, Jamison KR. Manic-depressive illness. Oxford University Press; New York: 1990
- McElroy SL, Keck PE Jr, Strakowski SM. Mania, psychosis and antipsychotics. J Clin Psychiatry 1996;57(Suppl 3):14-26
- Salvi V, D'Ambrosio V, Rosso G, Age-specific prevalence of metabolic syndrome in Italian patients with bipolar disorder. Psychiatry Clin Neurosci 2011;65:47-54
- Guan N, Liu H, Diao F, Prevalence of metabolic syndrome in bipolar patients initiating acute-phase treatment: a 6-month follow up. Psychiatry Clin Neurosci 2010;64:625-33
- Keck PE Jr, McElroy SL. Outcome in the pharmacologic treatment of bipolar disorder. J Clin Psychopharmacol 1996;16(Suppl 1):15S-23S
- Keck PE Jr, Kessler RC, Ross R. Clinical and economic effects of unrecognized or inadequately treated bipolar disorder. J Psychiatr Pract 2008;14(Suppl 2):31-8
- Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL. editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 11th edition. McGraw-Hill Press; New York: 2006. p. 461-500
- Abilify US PI. Available from: http://www.abilify.com/pdf/pi.aspx?tc=89340&utm_source=google&utm_medium=organic_search&utm_term=Abilify+&q=Abilify+&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a [Accessed 10 May 2011]
- Saphris US PI. Available from: http://www.saphris.com/ [Accessed 10 May 2011]
- Zyprexa US PI. Available from: http://www.zyprexa.com/Pages/index.aspx [Accessed 10 May 2011]
- Seroquel and Seroquel XR US PI. Available from: roquelxrtouchpoints.com/ [Accessed 10 May 2011]
- Risperdal US PI. Available from: http://www.risperdal.com/prescribing.html [Accessed 10 May 2011]
- Geodon USPI. Available from: http://media.pfizer.com/files/products/uspi_geodon.pdf [Accessed 10 May 2011]
- EMEA. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&murl=menus%2Fmedicines%2Fmedicines.jsp&mid=WC0b01ac058001d125&searchTab=&alreadyLoaded=true&status=Authorised&status= Withdrawn&status=Suspended&status=Refused&startLetter=A&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=generics [Accessed 10 May 2011]
- Sacchetti E, Galluzzo A, Valsecchi P. Oral ziprasidone in the treatment of patients with bipolar disorder: a critical review. Expert Rev Clin Pharmacol 2011;4:163-79
- Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003;64(Suppl 19):6-12
- Fagiolini A, Canas F, Gallhofer B, Strategies for successful clinical management of schizophrenia with ziprasidone. Expert Opin Pharmacother 2010;11:2199-220
- Ziprasidone capsules, Summary of Product Characteristics. Available from: http://www.lakemedelsverket.se/english/Search-the-website/?q=ziprasidone [Accessed 04 March 2011]
- Gandelman K, Alderman JA, Glue P, The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychiatry 2009;70(1):58-62
- Meyer JDrug-drug interactions with antipsychotics. CNS Spectrums 2007. Available from: http://www.cnsspectrums.com/aspx/articledetail.aspx?articleid=1653
- Correll CU. From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010;25(Suppl 2):S12-20
- Keck PE Jr, Versiani M, Potkin S, Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160(4):741-8
- Potkin SG, Keck PE Jr, Segal S, Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005;25:301-10
- Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978;35(7):873-4
- First MB, Spitzer RL, Gibbon M, Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York State Psychiatric Institute, Biometrics Research; New York: 2001
- Guy W. Early Clinical Drug Evaluation Manual. United States Department of Health, Education, and Welfare; Washington, DC: 1976. p. 217-22; 534–7
- Vieta E, Ramey T, Keller D, Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol 2010;24:547-58
- Data on file, Pfizer, Inc
- Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76
- Dunner DL. Atypical antipsychotics: efficacy across bipolar disorder subpopulations. J Clin Psychiatry 2005;66(Suppl 3):20-7
- Potkin SG, Keck PE Jr, Giller E, Ziprasidone in bipolar mania: efficacy across patient subgroups. Poster presented at 157th Annual Meeting of the American Psychiatric Association, May 1-6, 2004, New York, NY, USA
- Stahl S, Lombardo I, Loebel A, Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. J Affect Disord 2010;122:39-45
- Weisler R, Warrington L, Dunn J, Adjunctive ziprasidone in bipolar mania: short- and long-term data. Poster presented at the 157th Annual Meeting of the American Psychiatric Association 2004, May 1-6, New York (NY)
- Vieta E, Pappadopulos E, Mandel FS, Lombardo I. Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study. Int J Neuropsychopharmacol 2011;14:1-11
- Keck PE Jr, Versiani M, Warrington L, Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania. J Clin Psychiatry 2009;70:844-51
- Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
- Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6
- Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
- Montgomery SM, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
- Warrington L, Lombardo I, Loebel A, Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder. CNS Drugs 2007;21:835-49
- Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 1993;72:17B-22B
- Bowden CL, Vieta E, Ice KS, Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010;71:130-7
- Yildiz A, Vieta E, Leucht S, Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011;36:375-89
- Young RC, Biggs JT, Ziegler VE, A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35
- Perlis RH, Welge JA, Vornik LA, Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006;67:509-16
- Smith LA, Cornelius V, Warnock A, Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007;9:551-60
- Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin Ther 2009;31:1345-59
- Rossi A, Canas F, Fagiolini A, Switching among antipsychotics in everyday clinical practice: focus on ziprasidone. Postgrad Med 2011;123:135-59
- Mamo D, Kapur S, Shammi CM, A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004;161:818-25
- American Psychiatric Association. Practice Guideline for the Treatment of Patients with Bipolar Disorder. 2002. Available from: http://www.psychiatryonline.com/pracGuide/pracGuideTopic_8.aspx [Accessed March 2011]
- Yatham LN, Kennedy SH, Schaffer A, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009;11:225-55
- Grunze H, Vieta E, Goodwin GM, The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009;10:85-116
- Grunze H, Vieta E, Goodwin GM, The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11:81-109
- National Institute for Clinical Excellence. CG 38. Bipolar Disorder: NICE Guideline. 2006. Available from: http://www.nice.org.uk/nicemedia/live/10990/30193/30193.pdf [March 2011]
- Goodwin GM. Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition–recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23:346-88
- Montes J-M. Use of ziprasidone in patients with schizophrenia in Europe. Eur Psychiatry 2011;26(special number 1):29-37
- Hermes E, Nasrallah H, Davis V, The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res 2011;128:166-70
- Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24:192-208
- Gardner DM, Murphy AL, O'Donnell H, International consensus study of antipsychotic dosing. Am J Psychiatry 2010;167:686-93
- Andreasen NC, Pressler M, Nopoulos P, Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010;67:255-62
- Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-7